Drug news
EU gives extended CE Mark Approval to ExAblate System (InsighTec) for Bone Tumours
The ExAblate System, from InsighTec, has received an extended European CE Mark for the local treatment of cancerous and benign primary and secondary Bone Tumors, including but not limited to Multiple Myeloma, Bone Metastases, Osteoid Osteoma as well as facet joint back Pain. The CE mark applies to the ExAblate 2000 and 2100 as well as the ExAblate 2100 Conformal Bone System. The CE mark was based on additional published clinical evidence.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.